Taylor Law Firm, LLC Legal Blog

Serving Alabama, Mississippi & Florida including Mobile, Pascagoula, Gulfport, Biloxi & Pensacola

Yaz, Yasmin Settlements Reach $142 Million

Thu, 05/17/2012

Bayer recently announced that settlements of U.S. lawsuits which claim Yasmin causes blood clots in women have increased to $142 million. This involves the settlement of 651 cases involving Yasmin and Yaz contraceptives. The statement was made in Bayer's Stockholders' Newsletter for the first quarter. This works out to about $218,000 a case.

What to Do after a Car Accident?

Wed, 05/16/2012

If you have been involved in a car accident, your conduct in the next minutes, hours, and days can make all the difference in your ability to recover compensation in a lawsuit.

First, make sure everyone is out of immediate danger. If anyone is in immediate danger, provide help if you can do so safely.

If possible, move vehicles from traffic.

Contact police and other emergency responders.

Health Canada Issues Actos Warning

Tue, 05/01/2012

Health Canada issued a warning on April 19, 2012 that Actos may increase the risk of bladder cancer. Pursuant to an agreement with the manufacturer, Takeda, the label to the drug will be changed to address the risk. As many of you will remember, the FDA issued a similar warning on June 15, 2011 which associated Actos with bladder cancer.

Bill to Allow Suits Against Generic Manufacturers

Fri, 04/20/2012

As you may know from earlier postings, a Supreme Court decision last year in Pliva v. Mensing effectively makes it impossible for patients injured by generic drugs to sue the manufacturer. The court ruled that the generic manufacturers do not have control over what their labels say and cannot be held responsible for failing to alert patients about a drug's risks. This ruling bars many cases which are currently pending in courts across the country.

Nursing Home Care is Bad Despite High Profits

Tue, 04/10/2012

Families for Better Care, a citizen advocacy organization, said recently through its executive director, Brian Lee, that despite "astonishing" earnings reports for publicly traded nursing homes, the care remains "mediocre at best." "The industry's own reports show...surging revenues, strong profits, and expansion through acquisitions...while failing to consistently provide quality care."

FDA Concludes Yaz, Yasmin May Cause Blood Clots

Tue, 04/10/2012

An alert from the FDA today stated that it has completed its review of observational studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills (Yaz, Yasmin, Beyaz). FDA has concluded that these pills may be associated with a higher risk for blood clots than other progestin-containing pills.

New Warnings Added to Celexa

Mon, 04/02/2012

The FDA recently announced that the drug Celexa (citalopram hydrobromide) would have new warnings added to its label. The warnings discourage patients with underlying heart conditions and patients predisposed to having low blood levels of potassium and magnesium from using the drug. The label indicates that the drug is "not recommended" for these patients. The label was also changed to state lower doses that should be used in patients over 60 years old.

BP Oil Spill Settlement

Thu, 03/22/2012

BP announced earlier this month that they reached a settlement with the Plaintiff's Steering Committee in the litigation in federal court in New Orleans over the Gulf oil spill. It has been reported that the settlement is estimated at $7.8 billion. Actually, there is no cap on the settlement. Ultimately, the amount of the settlement will depend on how many claims are filed and the amount of damages proven.

Ex-employee Says Takeda Hid Actos Cancer Cases

Tue, 03/13/2012

A former medical reviewer in the pharmacovigilance division of Takeda Pharmaceuticals has filed a lawsuit saying the drugmaker hid bladder cancer adverse events involving the drug, Actos. As we have reported previously, concerns that Actos raises the risk of bladder cancer for some users has resulted in hundreds of lawsuits filed against Takeda, which have now been consolidated in a Louisiana federal court.

Pradaxa Effects May Be Irreversible

Wed, 03/07/2012

A recent case report in the Journal of Neurosurgery indicates that bleeding complications from Boehringer Ingelheim's blood clot preventer, Pradaxa, may be irreversible. The report describes the death of an 83 year old man who had a routine ground level fall at home. He had been started on dabigatran, known by the commercial name Pradaxa, one month earlier for atrial fibrillation. Atrial fibrillation is known to increase the risk of stroke and death.

855.646.4355
316 Magnolia Ave., Fairhope, AL 36532